4D Molecular Therapeutics announced that it has commenced an underwritten public offering of $250M of shares of its common stock. All of the shares in the proposed offering are to be sold by 4D Molecular Therapeutics. Goldman Sachs & Co., BofA Securities, Jefferies and Barclays are acting as joint book-running managers for the proposed offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FDMT:
- 4D Molecular presents interim data from Randomized Phase 2 PRISM trial
- 4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
- 4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
- 4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
- 4D Molecular receives RPDD from FDA for aerosolized 4D-710
